4-methoxyamphetamine has been researched along with sirolimus in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.90) | 29.6817 |
| 2010's | 16 (55.17) | 24.3611 |
| 2020's | 11 (37.93) | 2.80 |
| Authors | Studies |
|---|---|
| Carrozza, JP; Cohen, DJ; Cutlip, DE; Ho, KK; Jeremias, A; Kirtane, AJ; Lee, T; Pinto, DS; Ruisi, CP; Sylvia, B | 1 |
| Aharonian, VJ; Brar, SK; Brar, SS; Dangas, G; Gray, WA; Leon, MB; Moses, JW | 1 |
| Fujiwara, M; Kato, Y; Mimura, A; Shiode, N; Shirota, K; Tsunoda, F | 1 |
| Chia, PL; Earnest, A; Lim, J | 1 |
| Fahy, M; Kedhi, E; Kereiakes, DJ; Parise, H; Serruys, PW; Smits, PC; Stone, GW | 1 |
| Hara, K; Hasegawa, K; Hibi, K; Ikari, Y; Ishiwata, S; Isshiki, T; Katsuki, T; Kimura, K; Kiyooka, T; Koyama, Y; Kozuma, K; Sano, K; Takahashi, N; Tanabe, K; Uehara, Y; Yamane, M; Yokoi, H | 1 |
| Fuke, S; Ikeda, T; Kawai, H; Morimoto, Y; Ono, T; Saito, H; Sato, T | 1 |
| Bøtker, HE; Christiansen, EH; Hansen, HS; Hansen, KN; Jensen, LO; Kaltoft, A; Krusell, LR; Lassen, JF; Madsen, M; Maeng, M; Ravkilde, J; Thayssen, P; Thuesen, L; Tilsted, HH | 1 |
| Antoniucci, D; Carrabba, N; Dovellini, EV; Migliorini, A; Parodi, G; Valenti, R; Vergara, R | 1 |
| Byrne, RA; Cassese, S; Kastrati, A; King, L; Mehilli, J; Schömig, A; Schulz, S; Tada, T | 1 |
| Ajioka, M; Aoyama, Y; Hiramatsu, M; Hirayama, H; Ishikawa, K; Kamiya, H; Kato, K; Tanaka, A; Tanaka, T | 1 |
| Ahn, HS; Chae, IH; Kandzari, DE; Kang, HJ; Kang, J; Kang, SH; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, KW; Park, YB; Youn, TJ | 1 |
| Dias, S; Petrou, P | 1 |
| Abizaid, A; Byrne, J; Carrié, D; Christiansen, EH; Copt, S; Garot, P; Greene, S; Gregson, J; Hovasse, T; Iñiguez, A; Krackhardt, F; Lurz, P; Maillard, L; Menown, IBA; Meredith, IT; Morice, MC; Naber, C; Ong, P; Pocock, SJ; Redwood, S; Stoll, HP; Talwar, S; Tresukosol, D; Urban, P; Windhövel, U | 1 |
| Airaksinen, J; Berland, J; Carrié, D; Christen, T; Dawkins, KD; Elhadad, S; Erglis, A; Janssens, L; Jobe, RL; Kereiakes, DJ; Masotti, M; Mehta, SR; Meredith, IT; Moreno, R; Reitman, A; Stein, B; Windecker, S | 1 |
| Amano, H; Fuku, Y; Goto, T; Habara, S; Kadota, K; Kubo, S; Otsuru, S; Tada, T; Tanaka, H | 1 |
| Dhingra, R; Kirshenbaum, LA; Ravandi, A | 1 |
| Anzuini, A; Bartorelli, A; Benassi, A; Beneduce, A; Briguori, C; Cappelletti, A; Chiarito, M; Colombo, A; De Martini, S; Fabbiocchi, F; Falcone, S; Ferrante, G; Godino, C; Ielasi, A; Locuratolo, N; Magni, V; Margonato, A; Montorfano, M; Parisi, R; Perfetti, G; Pierri, A; Pivato, CA; Prati, E; Reimers, B; Rutigliano, D; Tespilli, M | 1 |
| Christiansen, EH; Eftekhari, A; Ellert-Gregersen, J; Engstroem, T; Freeman, PM; Hansen, HS; Jakobsen, L; Jensen, LO; Kahlert, J; Maeng, M; Raungaard, B | 1 |
| Chang, CJ; Chou, SH; Hsiao, FC; Hsu, LA; Lee, HF; Lin, CP; Lin, YC; Tsai, CT; Tung, YC; Yu, FC | 1 |
| Aggarwal, P; Bhattacharjee, P; Jha, M; Karmakar, S; Krishna, V; Kumar, P; Mukherjee, P; Pandey, U; Ray, S; Razi, M; Sachan, M; Sharma, AK; Shukla, P; Sinha, SK; Thakur, R | 1 |
| Cequier, A; Choudhury, A; Colombo, A; de Winter, RJ; Gao, C; Garg, S; Hara, H; Hofma, SH; Kaul, U; Moreno, R; Ono, M; Onuma, Y; Petrov, I; Serruys, PW; Smits, PC; Tonino, PAL; Zaman, A | 1 |
| Christensen, MK; Christiansen, EH; Eftekhari, A; Ellert, J; Freeman, P; Hansen, HS; Jakobsen, L; Jensen, LO; Jensen, RV; Junker, A; Kahlert, J; Kristensen, SD; Maeng, M; Raungaard, B; Støttrup, NB; Terkelsen, CJ; Thim, T; Veien, K | 1 |
| Arroyo, D; Benamer, H; Champagne, S; Chevalier, B; Garot, P; Gautier, A; Hovasse, T; Lefèvre, T; Neylon, A; Sanguineti, F; Unterseeh, T | 1 |
| Al-Shaibani, S; Arevalos, V; Bastos-Fernandez, G; Biscaglia, S; Bordes, P; Brugaletta, S; Campo, G; Diletti, R; Escaned, J; Flores, X; Gabani, R; Gomez-Hospital, JA; Gomez-Lara, J; Gonzalo, N; Grima Sopesens, N; Ielasi, A; Iñiguez, A; Jimenez, M; Jimenez-Diaz, V; Jiménez-Quevedo, P; Lenzen, M; Maristany, J; Ortega-Paz, L; Oyarzabal, L; Pineda, J; Rodes-Cabau, J; Romaguera, R; Sabaté, M; Serra, A; Serruys, PW; Silvestro, A; Spione, F; Tebaldi, M; Tespili, M | 1 |
| Bennett, J; Cutlip, DE; Doros, G; Garcia-Garcia, HM; Gharib, EG; Kandzari, DE; Koolen, JJ; Roguin, A; Waksman, R | 1 |
| Abdellaoui, M; Berland, J; Brunel, P; Carrié, D; Copt, S; Dibie, A; Garot, P; Karsenty, B; Levy, R; Lipiecki, J; Morelle, JF; Morice, MC; Oldroyd, K; Robin, C; Sadozai Slama, S | 1 |
| Han, JK; Han, SH; Hur, SH; Hwang, D; Kang, HJ; Kang, J; Kim, HS; Kim, JW; Kim, SH; Kim, SY; Kim, W; Kim, YH; Koo, BK; Lee, N; Lee, SJ; Park, K; Park, KW; Park, SH; Shin, S; Yang, HM; Yang, S | 1 |
| Ahn, SG; Cho, S; Choi, HH; Choi, WG; Doh, JH; Heo, JH; Hong, BK; Jang, YS; Jeon, DW; Jeong, H; Kang, WC; Kwon, KH; Lee, BK; Lee, JW; Lee, NH; Lee, SH; Lim, SW; Park, JH; Yoo, SY; Yoon, J; Youn, YJ | 1 |
2 review(s) available for 4-methoxyamphetamine and sirolimus
| Article | Year |
|---|---|
Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials.
Topics: Coronary Angiography; Death; Drug-Eluting Stents; Equipment Design; Humans; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Recurrence; Risk; Sirolimus; Thrombosis; Treatment Outcome | 2009 |
A mixed treatment comparison for short- and long-term outcomes of bare-metal and drug-eluting coronary stents.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Death; Drug-Eluting Stents; Everolimus; Humans; Immunosuppressive Agents; Male; Metals; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Sirolimus; Stents; Thrombosis; Treatment Outcome | 2016 |
12 trial(s) available for 4-methoxyamphetamine and sirolimus
| Article | Year |
|---|---|
Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Death; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Proportional Hazards Models; Prospective Studies; Single-Blind Method; Sirolimus | 2011 |
Sirolimus eluting coronary stent implantation in patients on maintenance hemodialysis: the OUCH study (outcome of cypher stent inhemodialysis patients).
Topics: Aged; Coronary Disease; Death; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; Kidney Function Tests; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Prospective Studies; Renal Dialysis; Sirolimus; Time Factors; Vascular Calcification | 2012 |
2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Death; Denmark; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Single-Blind Method; Sirolimus; Thrombosis; Treatment Outcome | 2012 |
Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Death; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Prosthesis Design; Risk Assessment; Sirolimus; Thrombosis; Treatment Outcome | 2013 |
Usefulness of the SYNTAX and clinical SYNTAX scores in predicting clinical outcome after unrestricted use of sirolimus- and everolimus-eluting Stents.
Topics: Aged; Death; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Percutaneous Coronary Intervention; Registries; Retrospective Studies; Sirolimus | 2013 |
2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Disease; Coronary Thrombosis; Death; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk; Sirolimus; Statistics as Topic; Stents; Survival Rate | 2017 |
Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Death; Diabetes Complications; Diabetes Mellitus; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Polymers; Sirolimus; Treatment Outcome | 2017 |
Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial.
Topics: Absorbable Implants; Coronary Artery Disease; Death; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Polymers; Prospective Studies; Sirolimus; Stents; Treatment Outcome | 2022 |
Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.
Topics: Death; Drug-Eluting Stents; Everolimus; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Sirolimus; Stents; Thrombosis; Treatment Outcome | 2022 |
Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent.
Topics: Absorbable Implants; Antigens, CD34; Coronary Artery Disease; Death; Diabetes Mellitus; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prosthesis Design; Sirolimus; Stents; Treatment Outcome | 2022 |
Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes.
Topics: Absorbable Implants; Cardiovascular Agents; Coronary Artery Disease; Death; Drug-Eluting Stents; Everolimus; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Polymers; Prospective Studies; Prosthesis Design; Sirolimus; Treatment Outcome | 2022 |
Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
Topics: Aged; Death; Drug-Eluting Stents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Treatment Outcome | 2023 |
15 other study(ies) available for 4-methoxyamphetamine and sirolimus
| Article | Year |
|---|---|
Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'.
Topics: Aged; Anti-Inflammatory Agents; Coronary Restenosis; Coronary Stenosis; Death; Drug-Eluting Stents; Eligibility Determination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Revascularization; Patient Selection; Randomized Controlled Trials as Topic; Registries; Reproducibility of Results; Sirolimus | 2008 |
Late progression after sirolimus-eluting stent implantation for de novo lesions--comparison with bare metal stent implantation.
Topics: Aged; Aged, 80 and over; Constriction, Pathologic; Death; Disease Progression; Drug-Eluting Stents; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Sirolimus; Stents; Treatment Outcome | 2010 |
Biolimus-eluting biodegradable polymer-coated stent versus bare metal stent in acute ST-elevation and non-ST elevation myocardial infarction: Justification for biodegradable polymer-coated stent in acute coronary syndrome (JANICE) registry.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Death; Drug-Eluting Stents; Female; Humans; Male; Metals; Middle Aged; Myocardial Infarction; Observation; Polymers; Registries; Retrospective Studies; Safety; Sirolimus; Stents; Treatment Outcome | 2011 |
Five-year clinical outcomes after implantation of sirolimus-eluting stents in patients with and without diabetes mellitus.
Topics: Aged; Coronary Angiography; Death; Diabetes Mellitus; Drug-Eluting Stents; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prognosis; Risk Factors; Sirolimus; Thrombosis; Treatment Outcome | 2012 |
Clinical and angiographic outcomes of patients treated with everolimus-eluting stents or first-generation Paclitaxel-eluting stents for unprotected left main disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Death; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Postoperative Complications; Registries; Sirolimus; Treatment Outcome | 2012 |
Treatment of sirolimus-eluting stent restenosis: additional stent, balloon angioplasty, and coronary artery bypass graft.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Restenosis; Death; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Radiography; Retrospective Studies; Sirolimus; Treatment Outcome | 2013 |
Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation.
Topics: Aged; Aspirin; Death; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prosthesis Implantation; Pyridines; Retrospective Studies; Sirolimus; Staining and Labeling; Thrombosis; Time Factors; Treatment Outcome | 2017 |
Ferroptosis: beating on death's door.
Topics: Apoptosis; Death; Humans; Iron; Myocytes, Cardiac; Sirolimus | 2018 |
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
Topics: Absorbable Implants; Aged; Anti-Bacterial Agents; Death; Drug-Eluting Stents; Female; Follow-Up Studies; Heart Diseases; Humans; Italy; Male; Middle Aged; Population Surveillance; Registries; Retrospective Studies; Sirolimus; Time Factors; Treatment Outcome | 2018 |
Procedural and One-Year Clinical Outcomes of Long 48 mm Xience Xpedition Everolimus-Eluting Stent in Complex Long Diffuse Coronary Artery Lesions.
Topics: Coronary Artery Disease; Coronary Vessels; Death; Drug-Eluting Stents; Everolimus; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Percutaneous Coronary Intervention; Prosthesis Design; Retrospective Studies; Sirolimus; Stents; Treatment Outcome | 2022 |
Twelve-month clinical outcomes of "nano-crush technique" for the treatment of bifurcation lesions using ultra-thin (60 µm) sirolimus-eluting coronary stents.
Topics: Aged; Coronary Artery Disease; Death; Drug-Eluting Stents; Humans; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Sirolimus; Stents; Thrombosis; Treatment Outcome | 2023 |
Safety and efficacy of 48 mm Xience Xpedition everolimus-eluting stent for the treatment of long coronary lesions.
Topics: Cardiovascular Agents; Death; Drug-Eluting Stents; Everolimus; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Percutaneous Coronary Intervention; Prosthesis Design; Risk Factors; Sirolimus; Time Factors; Treatment Outcome | 2022 |
Sex Differences in 10-Year Outcomes Following STEMI: A Subanalysis From the EXAMINATION-EXTEND Trial.
Topics: Death; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Sex Characteristics; Sirolimus; ST Elevation Myocardial Infarction; Treatment Outcome | 2022 |
Comparison of outcomes in patients with or without ARC-HBR criteria undergoing PCI with polymer-free biolimus coated stents: The BioFreedom France study.
Topics: Coronary Artery Disease; Death; Drug-Eluting Stents; France; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Prosthesis Design; Sirolimus; Stents; Treatment Outcome | 2023 |
Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practice.
Topics: Coronary Artery Disease; Death; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Prosthesis Design; Sirolimus; Treatment Outcome | 2023 |